SGMOQ SANGAMO THERAPEUTICS INC revenue, earnings and financials

For the quarter ended March 31, 2026, SANGAMO THERAPEUTICS INC reported revenue of $1.44M (down 77.6% from a year earlier), net income of −$31.0M and diluted EPS of −$0.08; over the last four quarters revenue was $34.6M and net income −$123M; for the fiscal year ended December 2025 revenue was $39.6M, down 31.6% on the year before.

SGMOQ annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $39.6M, gross profit n/a, operating income −$121M, net income −$123M (margin -310.8%), EPS −$0.44
• Fiscal year ended Dec 2024: revenue $57.8M, gross profit n/a, operating income −$104M, net income −$97.9M (margin -169.4%), EPS −$0.49
• Fiscal year ended Dec 2023: revenue $176M, gross profit n/a, operating income −$274M, net income −$258M (margin -146.3%), EPS −$1.48
• Fiscal year ended Dec 2022: revenue $111M, gross profit n/a, operating income −$201M, net income −$192M (margin -172.8%), EPS −$1.25
• Fiscal year ended Dec 2021: revenue $111M, gross profit n/a, operating income −$183M, net income −$178M (margin -161.1%), EPS −$1.23

SGMOQ quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $1.44M (down 77.6% year over year), net income −$31.0M, EPS −$0.08
• Quarter ended Dec 31, 2025 (from the annual report): revenue $14.2M (up 88.4% year over year), net income −$37.4M, EPS −$0.11
• Quarter ended Sep 30, 2025: revenue $581K (down 98.8% year over year), net income −$34.9M, EPS −$0.11
• Quarter ended Jun 30, 2025: revenue $18.3M (up 5042.1% year over year), net income −$20.0M, EPS −$0.08
• Quarter ended Mar 31, 2025: revenue $6.44M (up 1238.3% year over year), net income −$30.6M, EPS −$0.14
• Quarter ended Dec 31, 2024 (from the annual report): revenue $7.55M (up 269.8% year over year), net income −$23.4M, EPS −$0.08
• Quarter ended Sep 30, 2024: revenue $49.4M (up 425.8% year over year), net income $10.7M, EPS $0.04
• Quarter ended Jun 30, 2024: revenue $356K (down 94.8% year over year), net income −$36.1M, EPS −$0.18
• Quarter ended Mar 31, 2024: revenue $481K (down 99.7% year over year), net income −$49.1M, EPS −$0.27
• Quarter ended Dec 31, 2023 (from the annual report): revenue $2.04M (down 92.5% year over year), net income −$60.3M, EPS −$0.35
• Quarter ended Sep 30, 2023: revenue $9.40M (down 64.5% year over year), net income −$104M, EPS −$0.59
• Quarter ended Jun 30, 2023: revenue $6.84M (down 76.7% year over year), net income −$115M, EPS −$0.66
• Quarter ended Mar 31, 2023: revenue $158M (up 459.5% year over year), net income $21.1M, EPS $0.12
• Quarter ended Dec 31, 2022 (from the annual report): revenue $27.2M (down 2.7% year over year), net income −$52.0M, EPS −$0.32
• Quarter ended Sep 30, 2022: revenue $26.5M (down 7.4% year over year), net income −$53.2M, EPS −$0.34
• Quarter ended Jun 30, 2022: revenue $29.4M (up 5.4% year over year), net income −$43.2M, EPS −$0.29
• Quarter ended Mar 31, 2022: revenue $28.2M (up 7.4% year over year), net income −$44.0M, EPS −$0.30
• Quarter ended Dec 31, 2021 (from the annual report): revenue $28.0M, net income −$37.5M, EPS −$0.25
• Quarter ended Sep 30, 2021: revenue $28.6M, net income −$47.7M, EPS −$0.33
• Quarter ended Jun 30, 2021: revenue $27.9M, net income −$47.2M, EPS −$0.33

SGMOQ cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$97.2M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$67.1M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$225M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$224M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$233M, share buybacks n/a

SGMOQ balance sheet

• Mar 31, 2026: cash $27.6M, total assets $60.0M, total liabilities $78.9M, shareholders' equity −$19.0M
• Dec 31, 2025: cash $20.9M, total assets $59.7M, total liabilities $74.0M, shareholders' equity −$14.3M
• Sep 30, 2025: cash $29.6M, total assets $88.6M, total liabilities $82.4M, shareholders' equity $6.24M
• Jun 30, 2025: cash $38.3M, total assets $97.6M, total liabilities $78.0M, shareholders' equity $19.6M
• Mar 31, 2025: cash $25.2M, total assets $86.2M, total liabilities $81.3M, shareholders' equity $4.91M
• Dec 31, 2024: cash $41.9M, total assets $102M, total liabilities $78.9M, shareholders' equity $22.8M
• Sep 30, 2024: cash $39.2M, total assets $111M, total liabilities $72.1M, shareholders' equity $39.1M
• Jun 30, 2024: cash $27.8M, total assets $93.0M, total liabilities $69.3M, shareholders' equity $23.7M

What is SGMOQ's revenue?

SANGAMO THERAPEUTICS INC reported $34.6M of revenue over its last four quarters, through March 31, 2026.

Is SGMOQ profitable?

No. SANGAMO THERAPEUTICS INC lost $123M over the last four quarters.

What is SGMOQ's EPS?

Diluted earnings per share over the last four quarters were −$0.38; −$0.08 in the latest quarter.

SGMOQ ownership and insider trades · All stocks